Literature DB >> 32780219

Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991-2016.

S Florentin1, Y Neumark2, S Raskin3, T Bdolah-Abram4, P Rosca5,6.   

Abstract

The co-occurrence of schizophrenia and substance use disorder (SUD) is clinically challenging and increasingly prevalent. This study compares trends in hospitalization characteristics of chronic psychotic patients with and without SUD in Israel, before and after introduction of the Community Rehabilitation of Persons with Mental Disability Law in 2000. The National Psychiatric Case Registry provided data on 18,684 adults with schizophrenia/schizoaffective disorders, hospitalized in 1991-2016 (at least once in 2010-2015). Repeated-measures ANOVA was used to measure the effect (and interactions) of group (patients with and without co-occurring disorders (COD)), time-period (Period1: 1991-2000, Period2: 2001-2009, Period3: 2010-2016) and age, on hospitalization measures-average length of stay (LOS), annual number of hospitalizations and hospitalization days. Among non-COD patients hospitalized in all three periods, LOS declined by half from 133.3 days in Period1 to 63.2 in Period3, and the annual number of hospitalizations increased slightly from 0.45 to 0.56. Among COD patients, LOS declined moderately from 82.7 days to 58.3 days, while annual hospitalizations increased dramatically from 0.56 to 0.82. The annual average number of hospitalization days/capita declined from 49.7 in Period1 to 26.3 in Period3 among non-COD patients, yet remained virtually unchanged among COD patients-39.6 and 37.4 in the two periods, respectively. Since introduction of the law, a significant improvement in hospitalization characteristics of chronic psychotic non-COD patients has been noted, whereas the situation worsened somewhat for COD patients. Community rehabilitation services for COD patients in Israel have yet to develop as a suitable alternative to hospitalization, and additional rehabilitation services are urgently needed.

Entities:  

Keywords:  Co-occurring disorders; LOS; Rehabilitation; SUD; Schizophrenia

Year:  2021        PMID: 32780219     DOI: 10.1007/s10488-020-01077-4

Source DB:  PubMed          Journal:  Adm Policy Ment Health        ISSN: 0894-587X


  26 in total

1.  Mental health reforms in Europe: Israel's rehabilitation in the community of persons with mental disabilities law: challenges and opportunities.

Authors:  Uri Aviram; Yigal Ginath; David Roe
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

2.  Long-term course of hospitalization for schizophrenia: Part II. Change with passage of time.

Authors:  W W Eaton; W Bilker; J M Haro; H Herrman; P B Mortensen; H Freeman; P Burgess
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

Review 3.  Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: A systematic review.

Authors:  Ana Adan; Arantxa Y Arredondo; Maria Del Mar Capella; Gemma Prat; Diego A Forero; José Francisco Navarro
Journal:  Neurosci Biobehav Rev       Date:  2017-02-07       Impact factor: 8.989

4.  Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.

Authors:  Robert E Drake; Alison E Luciano; Kim T Mueser; Nancy H Covell; Susan M Essock; Haiyi Xie; Gregory J McHugo
Journal:  Schizophr Bull       Date:  2015-08-19       Impact factor: 9.306

5.  Synthetic cannabinoid JWH-018 and psychosis: an explorative study.

Authors:  Susanna Every-Palmer
Journal:  Drug Alcohol Depend       Date:  2011-02-11       Impact factor: 4.492

6.  Psychiatric Hospitalizations of Chronic Psychotic Disorder Patients With and Without Dual Diagnosis, Israel, 1963-2016.

Authors:  S Florentin; P Rosca; S Raskin; T Bdolah-Abram; Y Neumark
Journal:  J Dual Diagn       Date:  2019-05-12

Review 7.  Cannabinoids and Psychosis.

Authors:  Deepak Cyril D'Souza; Rajiv Radhakrishnan; Mohamed Sherif; Jose Cortes-Briones; John Cahill; Swapnil Gupta; Patrick D Skosnik; Mohini Ranganathan
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

8.  Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors.

Authors:  A L Bahorik; C E Newhill; C C Queen; S M Eack
Journal:  Psychol Med       Date:  2013-04-03       Impact factor: 7.723

Review 9.  [CO-OCCURRING SCHIZOPHRENIA AND SUBSTANCE USE DISORDER: ETIOLOGICAL THEORIES AND CHALLENGES IN ISRAEL].

Authors:  Sharon Florentin; Sergey Raskin
Journal:  Harefuah       Date:  2017-11

10.  Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?

Authors:  Hagit Bonny-Noach
Journal:  Isr J Health Policy Res       Date:  2019-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.